Recommendations for the Management of Patients with Familial Hypercholesterolemia David I. FeldmanMichael J. BlahaSeth S. Martin New Drugs Approved for Homozygous FH (SS Virani, Section Editor) 14 November 2014 Article: 473
Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10? Dick C. ChanJing PangGerald F. Watts Statin Drugs (BS Wiggins, Section Editor) 15 November 2014 Article: 472
When Compliance Is an Issue—How to Enhance Statin Adherence and Address Adverse Effects Kim Birtcher Statin Drugs (BS Wiggins, Section Editor) 20 November 2014 Article: 471
Statins and Delirium: Is There a Role? Margarita TaburyanskayaTanna Hassig Statin Drugs (BS Wiggins, Section Editor) 15 November 2014 Article: 470
The Role of Microsomal Triglyceride Transfer Protein Inhibitors in the Treatment of Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Zahid AhmadAmit Khera New Drugs Approved for Homozygous FH (SS Virani, Section Editor) 20 November 2014 Article: 469
What the Guidelines Do Not Say: Statin Non-benefit Groups Pamela B. MorrisKellie McLain Statin Drugs (BS Wiggins, Section Editor) 11 November 2014 Article: 468
The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Recommendations Anandita AgarwalaPeter JonesVijay Nambi New Drugs Approved for Homozygous FH (SS Virani, Section Editor) 15 November 2014 Article: 467
Impact on Cognitive Function—Are All Statins the Same? Nishant P. ShahKristopher J. SwigerSeth S. Martin Statin Drugs (BS Wiggins, Section Editor) 15 November 2014 Article: 466
Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances Claudia StefanuttiGilbert R. Thompson New Drugs Approved for Homozygous FH (SS Virani, Section Editor) 20 November 2014 Article: 465